login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Cox-maze IV: new treatments for AF


Wednesday, 16 May 2007 00:00

Current treatments for atrial fibrillation (AF) include medications, electrical cadioversion (used to restore normal heart rhythm with an electric shock), radiofrequency ablation, surgery and atrial pacemakers. Some of these approaches are complex and time-consuming, therefore a new device has been developed that radically reduces surgery time as well as simplifies complex procedures used to treat persistent AF.

Heart surgeons at Washington University School of Medicine in St Louis, MO, have simplified a common surgical procedure used to treat AF, termed Cox-maze, in which they hope will be made available to more patients. The new procedure, Cox-maze IV could potentially replace the older 'cut and sew' Cox-maze III, in which ten precisely placed incisions in the heart muscle created a 'maze' to redirect errant electrical impulses.

In a recent study published in the February issue of Journal of Thoracic and Cardiovascular Surgery,

Dr Ralph Damiano, the John Shoenberg professor of Surgery and chief of cardiac surgery at the School of Medicine and a cardiac surgeon at Barnes-Jewish Hospital, and colleagues compared surgical outcomes of patients undergoing the Cox-maze III procedure versus those of patients undergoing the Cox-maze IV procedure by using propensity analysis. According to the researchers, from April 1992 to July 2005, 242 patients underwent the Cox-maze procedure. Of these, 154 patients had the Cox-maze III procedure, and 88 had the Cox-maze IV procedure.

"Using the significant regression coefficients, each patient's propensity score was calculated, allowing selectively matched subgroups of 58 patients each," they reported. Late follow-up was available for 112 (97%) patients, and freedom from AF recurrence and survival was calculated at one year by using Kaplan-Meier analysis.

The new device is a clamp-like instrument that heats heart tissue using radiofrequency energy. By grasping areas of the heart within the jaws of the device, surgeons can create lines of ablation on the heart muscle. In the older Cox-maze III procedure, the lines of ablation were made by cutting the heart muscle, sewing the incisions back together and letting a scar form.

The results demonstrated that the use of bipolar radiofrequency ablation has simplified the Cox-maze procedure, making it applicable to virtually all patients with AF undergoing concomitant cardiac surgery.

"This technology has made the Cox-maze procedure much easier and quicker to perform," says Damiano. "Instead of reserving the Cox-maze procedure for a select group of patients, we would urge use of this device for virtually all patients who have AF and are scheduled for other cardiac surgery."

"The older Cox-maze procedure was a very complicated operation, and very few surgeons were willing to do it," said Damiano. "So we started working on new technology and helped develop an effective ablation device that simplifies the procedure. Not only is Cox-maze IV shorter, but with the new device the procedure is also much safer because there's a much lower risk of bleeding."

Damiano believes that their most recent study of Cox-maze IV is unique because the surgeons carefully matched the age, sex and cardiac conditions of a group of patients who underwent Cox-maze III in the past with patients undergoing Cox-maze IV. "This is the first documentation of the effectiveness of the ablation devices compared to the incisions of the Cox-maze III," Damiano says. "This operation is very effective, and we now use the Cox-maze IV technique exclusively."



Most popular


St Jude Medical completes acquisition of CardioMEMS
Monday, 02 Jun 2014
St Jude Medical has announced it has completed its acquisition of privately held CardioMEMS, developer of the CardioMEMS heart failure system. The acquisition was completed on 30 May 2014. St Jude Medical completes acquisition of CardioMEMS

FDA approves CardioMEMS heart failure system
Monday, 02 Jun 2014
The US Food and Drug Administration has approved the CardioMEMS heart failure system that measures the pulmonary artery pressures and heart rates of patients with New York Heart Association (NYHA) C... FDA approves CardioMEMS heart failure system

Friday, 04 Jul 2014
A new study suggests that transradial access in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention is associated with reduced bleeding ... Transradial access predicts survival in NSTEMI patients

Features


New approach for aortic valve replacement is feasible
Friday, 04 Jul 2014
According to a report in The Journal of Thoracic and Cardiovascular Surgery, totally endoscopic aortic valve replacement (TEAVR) is technically feasible. Lead author of the report Marco Vola talks to ... New approach for aortic valve replacement is feasible

“Interventional cardiology is losing more than 50% of the talent pool”
Thursday, 05 Jun 2014
The Women Committee of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) has been set up to attain gender equality in interventional cardiology at the professional and ... “Interventional cardiology is losing more than 50% of the talent pool”

Profiles


David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Ashok Seth
Wednesday, 12 Feb 2014
Ashok Seth is the immediate past president of Cardiological Society of India and is the principal ... Ashok Seth

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions